Management of Patients with Chronic Hepatitis B and Antiviral Resistance
This answer is incorrect. With lamivudine monotherapy, resistance frequently develops. As many as 17-32% of patients develop the M204V/I mutation (in the tyrosine-methionine-aspartate-aspartate [YMDD] motif) after one year of therapy and nearly 70% of patients develop resistance after 4 years of lamivudine therapy. Thus, for this patient who is taking lamivudine and has a HBV DNA level of 106 IU/ml it is very likely this patient has developed resistance to lamivudine.
Choose another answer: